A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)

Clinical trial NCT07672223 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07672223
Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2026-06-25
Primary completion: 2029-09-30
Enrollment: 570

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.